KRAS and non-small cell lung carcinoma: HRS-4642 is a highly selective G12D inhibitor currently being evaluated in a Phase I clinical trial in China (NCT05533463), with preliminary results indicating an ORR of 33% in patients with NSCLC and CRC.399 INCB161734 is under development for the treatment of advanced and metastatic solid tumors with KRAS G12D mutation, in particular PDAC, CRC, and NSCLC (NCT06179160).